https://www.selleckchem.com/pr....oducts/gsk2126458.ht
Recently, we discovered a new glucogenic and centrally acting orexigenic hormone - asprosin. Asprosin is elevated in metabolic syndrome (MS) patients, and its genetic loss results in reduced appetite, leanness, and blood glucose burden, leading to protection from MS. We generated three independent monoclonal antibodies (mAbs) that recognize unique asprosin epitopes and investigated their preclinical efficacy and tolerability in the treatment of MS. Anti-asprosin mAbs from three distinct species lowered appetite and body weight, and r
Like
Comment
Share
